What your GLP-1 blood tests mean before the first dose, during dose changes, and when a flagged result calls for a conversation with your prescriber.

If you're starting semaglutide or tirzepatide, you'll probably hear about GLP-1 blood tests before your first injection. The results can look like a page of numbers with no context. This post focuses less on which tests to order and more on the conversation around them: when to test, how to read a flag, and what to bring to your prescriber.

Why a baseline matters before the first dose

A baseline gives you and your prescriber a starting point. Later changes can be compared against something measured instead of remembered. Without one, a slightly high creatinine six months in is much harder to interpret.

The prescribing information for these drugs includes warnings on pancreatitis, gallbladder disease, acute kidney injury that can follow dehydration from vomiting or diarrhea, and low blood sugar when the medication is combined with insulin or a sulfonylurea. Those warnings are the reason kidney and liver markers come up in the conversation. A single lab result does not predict a problem on its own.

People without diabetes are often tested too, usually because of weight, cardiovascular risk, or a routine baseline the prescriber likes to have. Ask why each test is ordered. A clear answer makes the results far easier to use. If you want a plain-language primer on these planning questions before your appointment, OzemNews has covered them in a way that's easy to skim.

The core baseline panel, marker by marker

Doctor typing on computer in office

HbA1c and fasting glucose

The ADA classifies prediabetes with an HbA1c of 5.7 to 6.4 percent and diabetes with 6.5 percent or higher. Those thresholds help sort out glucose status. They are not the only basis for dosing decisions, and your clinician will read them alongside your symptoms and history.

Kidney function

Most labs report serum creatinine and an eGFR calculated from it. Many use the CKD-EPI equation, but check the report, since labs can differ. A low eGFR prompts your clinician to ask about hydration, other medications, and blood pressure, and whether a repeat is needed. Electrolytes such as potassium and sodium matter here too, because vomiting and diarrhea can shift them quickly.

Liver enzymes

ALT and AST are the usual markers. Elevated values have many causes, and fatty liver is common and often has nothing to do with the medication. Your prescriber will read these numbers in context.

Lipid panel

Total cholesterol, LDL, HDL, and triglycerides can move with weight loss and dietary changes, whether or not you take the drug. Focus on the trend across draws rather than any single line.

Tests people often skip, and why they come up

Thyroid

TSH is a common baseline, but the boxed warning matters more than the number. The label warns about thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), and lists a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN 2) as a contraindication. That makes the history conversation the key part. Mention any thyroid cancer in your family, even if it happened decades ago.

Pregnancy

The label includes guidance on stopping the drug before a planned pregnancy and on contraception. The washout period is longer than many people expect, so check the current prescribing information for exact timing. Treat this as a planning conversation, not just a lab order.

Nutritional markers

Ferritin, vitamin B12, and vitamin D can become relevant when food intake drops substantially. Ask whether they fit your situation instead of assuming they belong on every order. Your clinician can decide based on your diet, symptoms, and history.

Lipase

Lipase is not a routine baseline for most people. It may come up if you have a history of gallstones or pancreatitis. Ask whether it makes sense for you and what your clinician would consider meaningful.

Rechecks during dose escalation

The ideal recheck interval depends on the patient, the reason for treatment, and the clinician. For people with diabetes, the ADA Standards of Care describe HbA1c checks at intervals, generally around every three months when therapy is changing and less often once goals are stable. Confirm the current recommendation with your clinician, since guidelines get updated.

Kidney function and electrolytes are the markers to watch after a stretch of vomiting, diarrhea, or poor fluid intake. In that scenario, a recheck may be requested sooner than the usual schedule. Weight loss can also shift glucose and lipids in either direction, so some changes will be favorable and others will surprise you. The clinician reads the pattern across draws.

Repeat labs during a dose change can help separate drug effects from illness or dietary shifts, but only if you record the timing and symptoms. Lining up each draw date against your dose changes is easier with a practical tracking reference on OzemNews.

Reading results without panic

Reference ranges differ between labs. Compare results from the same lab when you can, and note the range printed on each report. A value that looks high on one report may sit inside another lab's range.

One flagged value tells you less than a trend across two or three draws. A slightly abnormal creatinine after a bad stomach bug is very different from a steady climb over several months.

A flag is a prompt for a conversation, not an automatic stop signal. Clinicians typically repeat the test, check hydration, review other medications, or adjust the plan. Please don't stop a medication on your own based on one printout without talking to your prescriber first.

Bring printed results with dates, doses, and any symptoms from the week before each draw. Keeping a simple log, like the ones covered on OzemNews, makes the appointment faster and less stressful for both of you.

Red flags that need a call, not a wait for the next lab

Some symptoms shouldn't wait for your next scheduled draw. Severe or persistent abdominal pain, especially pain that radiates to the back, with or without vomiting, needs prompt medical attention. Pancreatitis is a labeled warning, so don't wait it out.

Signs of dehydration include very low urine output, dizziness when you stand, or being unable to keep fluids down. Call your clinician promptly, since dehydration is tied to the acute kidney injury warning in the label.

Yellowing of the skin or eyes, dark urine, or pale stools should be raised with a clinician promptly. Right upper abdominal pain or fever, especially alongside other gallbladder symptoms, also warrants a prompt call, because the label warns about gallbladder disease.

Bring these questions to your next appointment:

Why was each test ordered, and what does the result mean for my dose?
When is the next draw due, and should it happen sooner if my eating or drinking changes?
Which symptoms should trigger an earlier call?
Which of my results should I track between visits, and how should I log them?

FAQ

Do I need a baseline lab if I don't have diabetes?

Often yes, but it depends on your prescriber and your reasons for treatment. Ask why each test is ordered so you understand what it's meant to show.

Does a high creatinine mean I have to stop the medication?

Not automatically. A flagged value starts a conversation. Your clinician may repeat the test, check your hydration, or review your other medications before deciding anything.

How often should HbA1c be checked?

ADA guidance generally describes checks about every three months when therapy is changing, and less often once glucose goals are stable. Confirm the schedule that fits you with your prescriber.

Should I bring my results to every appointment?

Yes. Bring printed results with dates, doses, and any symptoms from the week before each draw. That context helps your clinician read the trend instead of a single number.

Sources

Why a baseline matters before the first dose